Michael Marino joined OptiNose in January 2017 as our Chief Legal Officer.  In this role, Mr. Marino will serve as Corporate Secretary to the Board of Directors and have overall responsibility for leading the legal function including legal and intellectual property strategy, risk management, compliance, contracting and advising the Company on strategic transactions, financings and corporate governance matters. Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and privately-held companies in a diverse range of industries – most notably life sciences.  Prior to joining OptiNose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell Science, Inc., a publicly-held cell and gene therapy company.  Prior to Fibrocell, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of NuPathe Inc., a publicly-held specialty pharmaceutical company, from 2010 until its acquisition by Teva Pharmaceuticals in 2014.  During his tenure at Fibrocell and NuPathe, Mr. Marino secured the issuance of numerous U.S. and foreign patents, successfully managed litigation matters, implemented and enhanced compliance programs, and led the legal negotiations for public and private financing transactions, licensing and collaboration arrangements and the sale of NuPathe. Before joining NuPathe, Mr, Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP in Philadelphia, PA and WilmerHale LLP in Boston, MA where his practice focused on mergers and acquisitions, collaborations, financing transactions, corporate governance, securities and other general corporate matters. Michael holds a Juris Doctor from Boston College Law School and a Bachelor of Science in Accountancy from Villanova University.

trategic transactions, financings and corporate governance matters, law,negotiations for public and private financing transactions